Treatment of oral candidiasis with methylene blue-mediated photodynamic therapy in an immunodeficient murine model

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics

Volumn 93, Issue 2, 2002, Pages 155-160

  Teichert, M C ^a   Jones, J W ^b   Usacheva, M N ^a   Biel, M A ^c  

^a Advanced Photodynamic Technologies Inc   (United States)

^b ABBOTT NORTHWESTERN HOSPITAL   (United States)

^c Nose and Throat Specialty Care of Minnesota   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; METHYLENE BLUE; PHOTOSENSITIZING AGENT; PYRROLE DERIVATIVE;

ANIMAL; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COUNT; CANDIDA ALBICANS; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; EVALUATION; METHODOLOGY; MICROBIOLOGY; MOUSE; MOUSE MUTANT; NUDE MOUSE; PHOTOCHEMOTHERAPY; THRUSH;

ANIMALS; ANTIFUNGAL AGENTS; AZOLES; CANDIDA ALBICANS; CANDIDIASIS, ORAL; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, FUNGAL; METHYLENE BLUE; MICE; MICE, NUDE; MICE, SCID; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS;

EID: 0036479831     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1067/moe.2002.120051     Document Type: Article

References (36)

1. Johnson EM, Warnock DW, Luker J, Porter SR, Scully C. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidiasis. J Antimicrob Chemother 1995;35:103-14.
2. Klein RS, Harris CA, Small CB, Moll R, Lesser M, Friedland GH. Oral candidiasis in high-risk patients as the initial manifestation of the acquired immunodeficiency syndrome. N Engl J Med 1984;311:354-8.
3. Powderly WG, Robinson K, Keath EJ. Molecular epidemiology of recurrent oral candidiasis in human immunodeficiency virus-positive patients: evidence for two patterns of recurrence. J Infect Dis 1993;168:463-6.
4. Sangeorzan JA, Bradley SF, He X, Zarins LT, Tiballi RN, Kauffman CA. Epidemiology of oral candidiasis in HIV-infected patients: colonization, infection, treatment, and emergence of fluconazole resistance. Am J Med 1994;97:339-46.
5. Biel MA. Photodynamic therapy and treatment of head and neck neoplasia. In: English G, editor. Otolaryngology. New York: Lippincott-Raven Publishers; 1996. p. 1-15.
6. Whelan WL, Kirsch DR, Kwon-Chung KJ, Wahl SM, Smith PD. Candida albicans in patients with the acquired immunodeficiency syndrome: absence of a novel or hypervirulent strain. J Infect Dis 1990;162:513-8.
7. Pankhurst C. Oropharyngeal candidiasis. Clin Evid 2001;4:761-72.
8. Diz Dios P, Ocampo A, Miralles C, Limeres J, Tomas I. Changing prevalence of human immunodeficiency virus-associated oral lesions. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;90:403-4.
9. Diz Dios P, Ocampo A, Miralles C, Otero I, Iglesias I, Rayo N. Frequency of oropharyngeal candidiasis in HIV-infected patients on protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;87:437-41.
10. Patton LL, McKaig R, Strauss R, Rogers D, Eron J. Changing prevalence of oral manifestations of human immunodeficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:299-304.
11. Martins MD, Lozano-Chiu M, Rex JH. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients. Clin Infect Dis 1998;27:1291-4.
12. Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of AIDS. AIDS Pat Care STDs 2000;14:627-35.
13. Hoegl L, Thoma-Greber E, Röcken M, Korting HC. HIV protease inhibitors influence the prevalence of oral candidosis in HIV-infected patients: a 2-year study. Mycoses 1998;41:321-5.
14. Cauda R, Tacconelli E, Tumbarello M, Morace G, De Bernardis F, Torosantucci A, et al. Role of protease inhibitors in preventing recurrent oral candidosis in patients with HIV infection: a prospective case-control study. J Acquir Immune Defic Syndr 1999;21:20-5.
15. Ito T. Toluidine blue: the mode of photodynamic action in yeast cells. Photochem Photobiol 1977;25:47-53.
16. Malik Z, Ladan H, Ehrenberg B, Nitzan Y. Bacterial and viral photodynamic inactivation. In: Henderson B, Dougherty T, editors. Photodynamic therapy: basic principles and clinical applications. New York: Marcell Dekker, Inc; 1992. p. 97-113.
17. Stenstrom K, Moan J, Brunborg G, Eklund T. Photodynamic inactivation of yeast cells sensitized by hematoporphyrin. Photochem Photobiol 1980;32:349-52.
18. Wilson M, Mia N. Sensitization of Candida albicans to killing by low power laser light. J Oral Pathol Med 1993;22:353-7.
19. AHFS Drug Information 2000.
20. Kupfer A, Aeschilmann C, Wermuth B, Cerny T. Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet 1994;343:763-4.
21. Canto M-IF, Setrakian S, Petras RE, Blades E, Chak A, Sivak MV. Methylene blue selectively stains intestinal metaplasia in Barrett's esophagus. Gastrointest Endosc 2000;44:1-7.
22. Chida K, Sato A, Nakamura S-I, Iwata M, Yasuda K, Shichi I, et al. A bronchofibroscopic analysis of the bronchial mucosa using a dye-scattering method for detection of bronchial lesions. Am Rev Respir Dis 1993;147:208-10.
23. Burrows GE. Methylene blue: effects and disposition in sheep. J Vet Pharmacol Ther 1984;7:225-31.
24. Fajer A. Effects of methylene blue added to a low fat diet in the mouse. Nature 1957;180:1054.
25. Macht DI, Harden WC. Toxicology and assay of methylene blue. Ann Intern Med 1933;7:739-45.
26. NTIS technical report: final report on the development of toxicity of methylene blue trihydrate in Sprague-Dawley (CD)Q rate. 1994.
27. NTP health and safety report, NTP chemical repository of methylene blue trihydrate 777220-79-3.
28. Schmidt VD, Haym J. Zum problem einer selektiven thermosensibilisierung von carcinomzellen in vivo mit vitamin K3-natriumbisulfit, methyleneblau und anderen thermosensibilisation. Arzneim Forsch 1968;18:676-83.
29. Wilheim R, Ivy AC. A preliminary study concerning the possibility of dietary carcinogenesis. Gastroenterology 1953;23:1-19.
30. Ladan H, Nitzan Y, Malik Z. The antibacterial activity of haemin compared with cobalt, zinc, and magnesium protoporphyrin and its effect on potassium and ultrastructure of Staphylococcus aureus. FEMS Microbiol Lett 1993;12:173-7.
31. Lacasse M, Fortier C, Chakir J, Côté L, Deslauriers N. Acquired resistance and persistence of Candida albicans following oral candidiasis in the mouse: a model of the carrier state in humans. Oral Microbiol Immunol 1993;8:313-8.
32. Cantorna M, Balish E. Mucosal and systemic candidiasis in congenitally immunodeficient mice. Infect Immun 1990;58:1093-100.
33. Mahanty S, Greenfield RA, Joyce WA, Kincade PW Inoculation candidiasis in a murine model of severe combined immunodeficiency syndrome. Infect Immun 1988;56:3162-6.
34. Von Lichtenberg F. Infectious diseases: fungal, protozoal, and helminth diseases and sarcoidosis. In: Cotran RS, Kumar V, Robbins SL, editors. Robinson pathology: Pathologic basis of disease, 4th ed. Philadelphia: WB Saunders Co; 1989. p. 386-8.
35. Navazesh M, Wood GJ, Brightman VJ. Relationship between salivary flow rates and Candida albicans counts. Oral Surg Oral Med Oral Pathol 1995;80:284-8.
36. Rhodus NL, Bloomquist C, Liljemark W, Bereuter J. Oral Candida albicans in patients with Sjögren's syndrome. Ear Nose Throat J 1999;78:47-53.